Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 07 Jun 2024 14:05:54 +0200Tue, 02 Apr 2024 13:05:00 +0200Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/cometriqHuman medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/cometriqTue, 02 Apr 2024 13:05:00 +0200Human medicineCometriq-PSUSA-00010180-201711 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)https://www.ema.europa.eu/system/files/documents/scientific-conclusion/wc500255367_en.pdfCometriq-PSUSA-00010180-201711 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)https://www.ema.europa.eu/system/files/documents/scientific-conclusion/wc500255367_en.pdfThu, 13 Sep 2018 02:00:00 +0200Human medicine